15 - References

References

Depression and anxiety disorders CHAPTER 3 References

1. Furukawa TA, et al. Meta-­analysis of effects and side effects of low dosage tricyclic antidepressants in depression: systematic review. BMJ 2002; 325:991.
2. Donoghue J, et al. Suboptimal use of antidepressants in the treatment of depression. CNS Drugs 2000; 13:365–368.
3. Lancaster SG, et al. Lofepramine: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in depressive illness. Drugs 1989; 37:123–140.
4. Montgomery SA, et  al. The optimal dosing regimen for citalopram: a meta-­analysis of nine placebo-­controlled studies. Int Clin Psychopharmacol 1994; 9 Suppl 1:35–40.
5. Burke WJ, et al. Fixed-­dose trial of the single isomer SSRI escitalopram in depressed outpatients. J Clin Psychiatry 2002; 63:331–336.
6. Altamura AC, et al. The evidence for 20mg a day of fluoxetine as the optimal dose in the treatment of depression. Br J Psychiatry Suppl 1988; (3):109–112.
7. Walczak DD, et al. The oral dose–effect relationship for fluvoxamine: a fixed-­dose comparison against placebo in depressed outpatients. Ann Clin Psychiatry 1996; 8:139–151.
8. Dunner DL, et al. Optimal dose regimen for paroxetine. J Clin Psychiatry 1992; 53 Suppl:21–26.
9. Moon CAL, et al. A double-­blind comparison of sertraline and clomipramine in the treatment of major depressive disorder and associative anxiety in general practice. J Psychopharmacol 1994; 8:171–176.
10. Loo H, et al. Determination of the dose of agomelatine, a melatoninergic agonist and selective 5-­HT(2C) antagonist, in the treatment of major depressive disorder: a placebo-­controlled dose range study. Int Clin Psychopharmacol 2002; 17:239–247.
11. Hewett K, et al. Eight-­week, placebo-­controlled, double-­blind comparison of the antidepressant efficacy and tolerability of bupropion XR and venlafaxine XR. J Psychopharmacol 2009; 23:531–538.
12. Kornstein SG, et al. The effect of desvenlafaxine 50 mg/day on a subpopulation of anxious/depressed patients: a pooled analysis of seven randomized, placebo-­controlled studies. Hum Psychopharmacol 2014; 29:492–501.
13. Iosifescu DV, et al. Efficacy and safety of axs-­05 (dextromethorphan-­bupropion) in patients with major depressive disorder: a phase 3 randomized clinical trial (GEMINI). J Clin Psychiatry 2022; 83:21m14345.
14. Goldstein DJ, et  al. Duloxetine in the treatment of depression: a double-­blind placebo-­controlled comparison with paroxetine. J Clin Psychopharmacol 2004; 24:389–399.
15. Detke MJ, et al. Duloxetine, 60 mg once daily, for major depressive disorder: a randomized double-­blind placebo-­controlled trial. J Clin Psychiatry 2002; 63:308–315.
16. Phillips B, et al. Gepirone: A new extended–release oral selective serotonin receptor agonist for major depressive disorder. J Pharm Technol 2024; 40:230–235.
17. He H, et al. Efficacy and tolerability of different doses of three new antidepressants for treating major depressive disorder: a PRISMA-­ compliant meta-­analysis. J Psychiatr Res 2018; 96:247–259.
18. Furukawa TA, et al. No benefit from flexible titration above minimum licensed dose in prescribing antidepressants for major depression: systematic review. Acta Psychiatr Scand 2020; 141:401–409.
19. Priest RG, et al. Moclobemide in the treatment of depression. Rev Contemp Pharmacother 1994; 5:35–43.
20. Schatzberg AF. Clinical efficacy of reboxetine in major depression. J Clin Psychiatry 2000; 61 Suppl 10:31–38.
21. Brogden RN, et al. Trazodone: a review of its pharmacological properties and therapeutic use in depression and anxiety. Drugs 1981; 21:401–429.
22. Feighner JP, et al. Efficacy of once-­daily venlafaxine extended release (XR) for symptoms of anxiety in depressed outpatients. J Affect Disord 1998; 47:55–62.